TenQ

The Philip Morris International story

Philip Morris International markets Marlboro outside the U.S. and is shifting toward IQOS and ZYN, with the central question whether smoke-free growth can reduce its reliance on cigarettes while restoring U.S. momentum.

Written from Philip Morris International's own filings with the SEC, and rewritten when it publishes a new earnings release. Updated 2026-09-30.

  • $193.76share price, last close
  • $302.0Bmarket value
  • 23/36TenQ Score checks passed
  • 10.3%growth a year the price assumes

The story in brief

  • Smoke-free margins advance. In the quarter to June 2026, smoke-free products contributed approximately 42% of net revenues, while International Smoke-Free adjusted gross margin reached 70.1%.
  • ZYN recovery remains uneven. U.S. ZYN shipments rose 1.8% to 2.9 billion pouches in the quarter to June 2026, but consumer offtake was flat to slightly growing in an expanding category.
  • Cash growth faces scrutiny. The reverse DCF implies 10.3% annual growth in free cash flow after stock pay, compared with 2.7% delivered annually over the last 10 years.

What drives the business

  • Philip Morris International's transition rests on over $16 billion invested in smoke-free products since 2008 and the November 2022 acquisition of Swedish Match, which brought ZYN alongside IQOS.
  • An agreement ending its U.S. IQOS commercial relationship with Altria gave PMI full U.S. commercialization rights as of April 30, 2024, extending the potential reach of its heated tobacco business.
  • Under the segment structure introduced in January 2026, International Combustibles remained the largest business in the quarter to June 2026, contributing $6.5 billion of revenue, compared with $3.9 billion from International Smoke-Free and $0.9 billion from the U.S.
  • IQOS shipment growth of 7.6% and VEEV shipment growth of 55.1% supported the quarter to June 2026, while pricing and product mix helped International Smoke-Free adjusted gross margin expand by 1.8 percentage points to 70.1%.
  • In August 2026, PMI's non-U.S. affiliates entered a cigarette contract manufacturing arrangement with Altria's Philip Morris USA, with initial shipments expected early in 2027 and no material impact expected on 2026 financial results.

What the price assumes

At $193.76, the reverse DCF assumes free cash flow after stock pay grows 10.3% a year for ten years, using a 10.2% discount rate.

That compares with 2.7% annual growth delivered over the last 10 years and the TenQ check's 3.4% bar, which moves the historical rate halfway toward 4%.

Over the last twelve months, PMI generated $12.7 billion of free cash flow before $162 million of stock-based pay, while its 4.2% free cash flow yield was below its historical 7.7%, failing the cash-yield comparison.

Value PM on your own assumptions

What could change the story

  • Smoke-free performance is less predictable than the established cigarette business, and U.S. organic gross profit declined 8.9% in the quarter to June 2026 as manufacturing expansion costs added pressure to broadly stable ZYN revenues.
  • Tax and flavor restrictions can interrupt IQOS adoption, as shown by consumer adjustment after Japan's excise-driven price increase and the characterizing flavor ban in Poland.
  • Updated projections for Canadian affiliate RBH prompted a $511 million non-cash impairment in the quarter to June 2026, reducing diluted EPS by 33 cents and leaving a carrying value of $51 million.
  • Total debt of $45.8 billion compared with $6.0 billion of cash and short-term investments, negative equity, and a near-term liquidity ratio of 0.98 account for failed TenQ balance-sheet checks despite positive free cash flow.
  • The Middle East conflict had mainly affected transport, energy and other input costs by the July 2026 earnings release, but PMI's full-year forecast did not assume a prolonged impact.

What to watch next

  • PMI's September 8, 2026 update raised full-year adjusted diluted EPS guidance to $8.35 to $8.50 and third-quarter guidance to $2.29 to $2.34 for currency only, leaving the underlying operating assumptions unchanged.
  • The operating benchmarks remain 5% to 7% organic revenue growth, 7% to 9% organic operating income growth, high-single digit smoke-free shipment growth and a 2% to 3% cigarette shipment decline for 2026.
  • U.S. ZYN consumer offtake, revenue and gross margin will show whether the expanded lineup and planned second-half investment strengthen performance following FDA Modified Risk Tobacco Product authorization for 20 ZYN variants.
  • Operating cash flow against guidance of around $13.5 billion and net debt to adjusted EBITDA against the company's expectation of close to 2.0x by the end of 2026 will show how the transition and debt reduction are progressing.

Sources

Back to the PM report